Insider Richard Miller reports 7.8% Corvus (CRVS) ownership in 13G/A
Rhea-AI Filing Summary
Corvus Pharmaceuticals, Inc. insider ownership is detailed in an amended Schedule 13G filing. As of December 31, 2025, Dr. Richard A. Miller is reported as the beneficial owner of 6,085,922 shares of common stock, or 7.8% of the class, based on 74,681,872 shares outstanding as of November 4, 2025.
Dr. Miller’s position includes 1,136,707 shares held directly, 1,188,103 shares held through the Miller-Horning Family Trust, and 3,761,112 shares underlying stock options that are vested or vest within 60 days of December 31, 2025. The Miller-Horning Family Trust and Dr. Sandra J. Horning each beneficially own 1,188,103 shares, representing 1.6% of the common stock.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What percentage of Corvus Pharmaceuticals (CRVS) is held by the Miller-Horning Family Trust?
The Miller-Horning Family Trust beneficially owns 1,188,103 shares of Corvus Pharmaceuticals common stock, equal to 1.6% of the outstanding shares. Richard A. Miller and Sandra J. Horning, as trustees, share voting and dispositive power over these trust-held shares.
What is Sandra J. Horning’s ownership stake in Corvus Pharmaceuticals (CRVS)?
Sandra J. Horning is reported as the beneficial owner of 1,188,103 shares of Corvus Pharmaceuticals common stock, representing 1.6% of the class. Her beneficial ownership arises through shared voting and dispositive power over shares held by the Miller-Horning Family Trust.
How were the ownership percentages for CRVS calculated in this Schedule 13G/A?
Ownership percentages are based on 74,681,872 shares of Corvus common stock outstanding as of November 4, 2025, as disclosed in a Form 10-Q. The filing also assumes exercise of stock options that are vested or will vest within 60 days of December 31, 2025.
What portion of Richard A. Miller’s CRVS stake consists of stock options?
Of Richard A. Miller’s 6,085,922 beneficially owned shares, 3,761,112 shares are underlying stock options that are vested or will vest within 60 days of December 31, 2025. These option shares are included when calculating his reported ownership percentage.
Does this Corvus Pharmaceuticals (CRVS) Schedule 13G/A indicate group ownership?
The filing identifies three reporting persons: Richard A. Miller, the Miller-Horning Family Trust, and Sandra J. Horning. It provides separate ownership and voting power figures for each, and the standard Schedule 13G group-related items are each marked “Not Applicable.”